Literature DB >> 15741257

Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life.

Nienke R Biermasz1, Alberto M Pereira, Jan W A Smit, Johannes A Romijn, Ferdinand Roelfsema.   

Abstract

Active acromegaly is associated with significant comorbidity and reduced quality of life. However, the prevalence of comorbidity after long-term remission is not established. Therefore, we assessed the presence of comorbidity in 118 patients in long-term remission after surgery, radiotherapy, and/or somatostatin analog treatment according to strict biochemical criteria of serum GH and IGF-I concentrations and evaluated the impact of comorbidity on quality of life. The mean duration of remission was 12.0 +/- 7.4 yr, and mean actual IGF-I sd scores were 0.6 +/- 1.7. Self-reported joint problems occurred in 77% of patients, hypertension in 37%, a history of myocardial infarction in 9%, and diabetes mellitus in 11%. The presence of joint problems was not related to GH and IGF-I levels, active disease duration, or age. Joint complaints had significant negative impact on quality of life. Patients with a history of myocardial infarction had reduced scores for general health, depression, and fatigue, and diabetes mellitus was associated with reduced scores for anxiety and sleep. In conclusion, acromegalic patients had a high prevalence of joint-related comorbidity and hypertension despite long-term control of GH excess. Especially, joint complaints contributed to a reduced perceived quality of life in these patients.

Entities:  

Mesh:

Year:  2005        PMID: 15741257     DOI: 10.1210/jc.2004-2297

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  53 in total

Review 1.  Somatostatin analog and pegvisomant combination therapy for acromegaly.

Authors:  Sebastian J C Neggers; Aart Jan van der Lely
Journal:  Nat Rev Endocrinol       Date:  2009-10       Impact factor: 43.330

2.  Biochemical and quality of life responses to octreotide-LAR in acromegaly.

Authors:  Ruth Mangupli; Paul Camperos; Susan M Webb
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

3.  Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire.

Authors:  Silvia Vandeva; Maria Yaneva; Emil Natchev; Atanaska Elenkova; Krasimir Kalinov; Sabina Zacharieva
Journal:  Endocrine       Date:  2015-01-06       Impact factor: 3.633

4.  Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders.

Authors:  Elena Valassi; Danielle J Brick; Jessica C Johnson; Beverly M K Biller; Anne Klibanski; Karen K Miller
Journal:  Endocr Pract       Date:  2012 Mar-Apr       Impact factor: 3.443

Review 5.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

6.  Is every joint symptom related to acromegaly?

Authors:  Gonca Örük; Figen Tarhan; Mehmet Argın; Mustafa Özmen
Journal:  Endocrine       Date:  2012-08-21       Impact factor: 3.633

7.  Adverse anthropometric risk profile in biochemically controlled acromegalic patients: comparison with an age- and gender-matched primary care population.

Authors:  C Dimopoulou; C Sievers; H U Wittchen; L Pieper; J Klotsche; J Roemmler; J Schopohl; H J Schneider; G K Stalla
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

8.  Persistent self-consciousness about facial appearance, measured with the Derriford appearance scale 59, in patients after long-term biochemical remission of acromegaly.

Authors:  S H P P Roerink; M A E M Wagenmakers; J F Wessels; R B T M Sterenborg; J W Smit; A R M M Hermus; R T Netea-Maier
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

9.  Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly.

Authors:  Agatha A van der Klaauw; Jeroen J Bax; Ferdinand Roelfsema; Marcel P M Stokkel; Gabe B Bleeker; Nienke R Biermasz; Johannes W A Smit; Johannes A Romijn; Alberto M Pereira
Journal:  Pituitary       Date:  2009-06-12       Impact factor: 4.107

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.